Faeth Therapeutics, Inc.

What they do

Faeth Therapeutics is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. Its lead asset, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway, currently in development for endometrial and breast cancer. The company was formed following the February 17, 2026 acquisition of Faeth Therapeutics by Sensei Biotherapeutics, Inc., which also completed a $200 million private placement financing. Prior to the acquisition, the company was developing solnerstotug, a conditionally active monoclonal antibody targeting the immune checkpoint VISTA.

Revenue drivers

• PIKTOR (Phase 2 endometrial cancer trial, FTH-PIK-201) — PIKTOR is the lead program; the company is not generating revenue and its value is tied to clinical progress in this ongoing Phase 2 trial.
• PIKTOR (Phase 1b/2 breast cancer trial, FTH-PIK-101) — Expanding PIKTOR into HR+/HER2- advanced breast cancer, with the first patient dosed in April 2026.

Recent performance

For the quarter ended June 30, 2026, the company reported a net loss of $16.0 million, or $2.84 per share, compared to a net loss of $4.9 million, or $3.91 per share, in the prior year period. Research and development expenses were $9.2 million, up from $2.5 million, primarily due to clinical and manufacturing costs for PIKTOR. General and administrative expenses were $9.2 million, up from $2.7 million, due to higher personnel costs and professional fees. As of June 30, 2026, the company held $186.4 million in cash, cash equivalents and marketable securities, including $183.1 million in net proceeds from the 2026 Private Placement. The company had an accumulated deficit of $469.4 million.

Strategy

The company's strategy centers on developing PIKTOR as a multi-node inhibitor of the PI3K/AKT/mTOR pathway across multiple cancer indications, with the thesis that simultaneous suppression produces deeper, more durable tumor suppression than single-node therapies. Management plans to use the $200 million in gross proceeds from the 2026 Private Placement to advance PIKTOR through key clinical milestones. The company is also completing the remaining portion of the solnerstotug Phase 1/2 trial with patients currently on study. Key leadership changes in June 2026 included the appointment of Anand Parikh as Chairman, President and CEO, and Brian Stephenson as CFO.

Risks

• Clinical trial failure risk — PIKTOR is in Phase 2 for endometrial cancer and Phase 1b/2 for breast cancer; failure to meet endpoints would be material.
• Regulatory approval risk — PIKTOR is investigational and not approved; there is no guarantee of regulatory success in any indication.
• Financing burn rate — The company has a history of significant operating losses and expects to continue incurring losses; the $186.4 million cash balance may not be sufficient for all planned development.
• Integration risk from acquisition — The February 2026 acquisition of Faeth Therapeutics and name change in June 2026 introduce integration and execution risks.

Outlook

Management expects to report topline data from the Phase 2 PIK-201 trial in second-line advanced endometrial cancer by year-end 2026. Interim data from the Phase 1b/2 PIK-101 trial in HR+/HER2- advanced breast cancer is expected in 2027. The company believes its $186.4 million in cash, cash equivalents and marketable securities will fund operations through these key clinical milestones.